Definium Therapeutics vs Legend Biotech
Definium Therapeutics (DFTX), health care, and Legend Biotech (LEGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Definium Therapeutics is worth $4B on the stock market and Legend Biotech $3.1B: Definium Therapeutics is valued at 29% more. Over the past year Definium Therapeutics's share price has moved +164% and Legend Biotech's -45.6%.
Key facts
- Definium Therapeutics market value
- $4B
- Legend Biotech market value
- $3.1B
- Legend Biotech revenue
- $1BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Definium Therapeutics | Legend Biotech |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4Bhigher | $3.1Blower |
| Revenue | — | $1B |
| Earnings | -$183.8Mhigher | -$296.8Mlower |
| Employees | 105lower | 3,300higher |
| Total assets | $440.1Mlower | $1.7Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | — | 3.0 |
| P/B | 4.2higher | 2.5lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | -13.3% |
| Balance sheet | ||
| Net assets | $332.3Mlower | $1Bhigher |
| Total liabilities | $107.8Mlower | $731.6Mhigher |
| Total debt | $40.6Mlower | $319.1Mhigher |
| Cash on hand | $257.8Mlower | $901.9Mhigher |
| Price change | ||
| Today | -2.59%lower | +0.75%higher |
| 1 year | +164%higher | -45.6%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Definium Therapeutics only (2)
Legend Biotech only (1)
- Zhang Lei20.8%
Percentages are each holding's share of that investor's reported portfolio. Who owns DFTX · Who owns LEGN
More on Definium Therapeutics
Further comparisons
Definium Therapeutics against its closest peers
Legend Biotech against its closest peers
Learn
Questions and answers
Which is bigger, Definium Therapeutics or Legend Biotech?
By market value, Definium Therapeutics is the larger: $4B against $3.1B for Legend Biotech.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Legend Biotech: $319.1M, against $40.6M for Definium Therapeutics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Definium Therapeutics and Legend Biotech?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Definium Therapeutics and 1 holds Legend Biotech.
Cite this page
Funkfolio, “Definium Therapeutics vs Legend Biotech”, data as of 18 November 2026. https://funkfolio.com/compare/dftx-vs-legn
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.